Latest VivoSim News & Updates

See the latest news and media coverage for VivoSim. We track all announcements, press releases, and industry mentions in real time, all in one place.

VivoSim

3D liver and intestine toxicology model provider

vivosim.ai

Headquarters: San Diego, United States
Founded year: 2007
Company type: Public company
Number of employees: 30–50
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about VivoSim

In short: VivoSim expanded into China, secured a $5M milestone payment from Eli Lilly, and presented high-accuracy toxicity data for its NAM models.

Company announcements

August 6 VivoSim

VivoSim regains Nasdaq compliance and updates financials

Received $5 million milestone and $1 million escrow release from Eli Lilly, completed $4 million financing, and holds $10.1 million cash.

July 21 VivoSim

VivoSim announces first commercial sales in China for NAMkind testing services

The two initial engagements with Chinese pharma companies mark a milestone in Asia-Pacific expansion and validate channel strategy.

July 16 VivoSim

VivoSim announces pricing of $4.0 million private placement

The placement is with a single healthcare-focused institutional investor and includes warrants exercisable at $0.85 per share.

July 15 VivoSim

VivoSim receives $5M milestone payment and forecasts 500%+ revenue growth

The milestone triggers upon Phase 2 patient dosing. VivoSim is eligible for up to $45 million additional payments.

Media coverage

August 12 Houston Chronicle

VivoSim Labs, Inc. (VIVS)

Options data delayed by 15 minutes. For real-time data, try AlphaSpace .

Never miss news about VivoSim

Track VivoSim and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.